[Ip-health] [MPP Statement] Access to Medicine Index 2016 Published Today with High Marks for Companies that License to the Medicines Patent Pool (MPP)

Katie Moore kmoore at medicinespatentpool.org
Mon Nov 14 06:54:12 PST 2016


[MPP Statement] Access to Medicine Index 2016 Published Today with High Marks for Companies that License to the Medicines Patent Pool (MPP)

Biennial ‘Report Card’ also notes that the MPP has been central driver of access-oriented licensing in the pharmaceutical industry

(GENEVA, November 14, 2016) – The Access to Medicine (ATM) Index issued its biennial report today giving high marks to companies that have negotiated licences for antiretrovirals and hepatitis C medicines through the Medicines Patent Pool (MPP). The report acknowledged that since the first company, Gilead, joined the MPP in 2012, the organisation has been "the central independent driver of access-oriented licensing in the pharmaceutical industry.”

The ATM index analyses the top twenty research companies on their approach to making medicines more accessible in low- and middle-income countries. Patents & Licensing is one of seven technical areas considered in the ranking. Top spots went to MPP partners Gilead Sciences, GlaxoSmithKline, Bristol-Myers Squibb and Merck & Co., while these companies as well as AbbVie were recognised for their “pro-access criteria in their agreed licences…negotiated by the MPP.”

“We welcome this year’s report and its focus on the high standards of MPP licences that seek to provide the broadest health benefits to people living in low- and middle- income countries,” said Greg Perry, Executive Director of the MPP. “We also congratulate our partners for their work to improve access to medicines policies in developing countries.”

The Index concludes that companies are "refining ways they organise efforts to increase access to medicine and most companies surveyed now have a detailed access-to-medicine strategy." While recognising that there is much room for further improvement, the ATM Index highlights certain companies’ initiatives to apply a more access-oriented approach to intellectual property management. “Licensing can stimulate competition, reduce prices and bolster supply,” notes ATM index reviewers. “To have a significant impact on access, licences should be non-exclusive, transparent and include access-friendly terms.”

Finally, the report indicates that more HIV/AIDS producers are covered today by voluntary licences than was the case in 2014, and, for the first time, companies are turning to voluntary licensing to expand access to medicines in a second disease area: hepatitis C. The MPP has signed licences for 12 World Health Organization-recommended antiretrovirals and one antiviral hepatitis C treatment with patent holders AbbVie, Bristol-Myers Squibb, Gilead Sciences, MSD (Merck & Co. in the US and Canada), US National Institutes of Health and ViiV Healthcare, a joint venture among GlaxoSmithKline, Pfizer and Shionogi.

 http://www.medicinespatentpool.org

- # # # -

About the Medicines Patent Pool
The Medicines Patent Pool is a United Nations-backed public health organisation working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income countries. Through its innovative business model, the MPP partners with industry, civil society, international organisations, patient groups and other stakeholders to prioritise, forecast and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations. To date, the MPP has signed agreements with six patent holders for twelve HIV antiretrovirals and for one hepatitis C direct-acting antiviral. Its generic partners have distributed more than three billion doses of low-cost medicines to 119 countries. The MPP was founded and remains fully funded by UNITAID.


Contact:

Katherine Moore
Head of Communications
Medicines Patent Pool
Tel: +41 22 533 5054 | Mobile: +41 79 825 4786
kmoore at medicinespatentpool.org<mailto:kmoore at medicinespatentpool.org>





More information about the Ip-health mailing list